Showing results (31-40 of 51) with videos related to
Sort By:
Pageof 6
Stroke|June 14, 2003
Effects of a selective CD11b/CD18 antagonist and recombinant human tissue plasminogen activator treatment alone and in combination in a rat embolic model of strokeLi Zhang, Zheng Gang Zhang, Rui Lan Zhang, et al.Journal of Biopharmaceutical Statistics|November 9, 2010
Viewpoints on the FDA draft adaptive designs guidance from the PhRMA working groupPaul Gallo, Keaven Anderson, Christy Chuang-Stein, et al.Journal of Clinical Psychopharmacology|November 18, 2008
An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorderSheldon H Preskorn, Bryan Baker, Sheela Kolluri, et al.Therapeutic Innovation & Regulatory Science|April 26, 2022
Accelerating the Availability of Medications to Pediatric Patients by Optimizing the Use of Extrapolation of EfficacyAllison Dunn, Dawoon Jung, Lisa L Bollinger, et al.Stroke|April 2, 2011
Risk and cumulative risk of stroke recurrence: a systematic review and meta-analysisKeerthi M Mohan, Charles D A Wolfe, Anthony G Rudd, et al.Neuroimage|March 16, 2006
Where the BOLD signal goes when alpha EEG leavesH Laufs, John L Holt, Robert Elfont, et al.Nature Reviews. Neuroscience|April 19, 2012
Impaired mitochondrial function in psychiatric disordersHusseini Manji, Tadafumi Kato, Nicholas A Di Prospero, et al.Innovations in Clinical Neuroscience|August 24, 2011
How Adaptive Trial Designs can Increase Efficiency in Psychiatric Drug Development: A Case StudyJoan Shen, Sheldon Preskorn, Vladimir Dragalin, et al.Journal of Pharmacokinetics and Pharmacodynamics|February 12, 2009
Evaluation of structural models to describe the effect of placebo upon the time course of major depressive disorderElizabeth Y Shang, Megan A Gibbs, Jaren W Landen, et al.Clinical Trials (London, England)|March 27, 2010
A Bayesian dose-finding trial with adaptive dose expansion to flexibly assess efficacy and safety of an investigational drugScott M Berry, Walter Spinelli, Gary S Littman, et al.Pageof 6